Basel: Sandoz has announced the European launch of Wyost (denosumab 120 mg) and Jubbonti (denosumab 60 mg). The medicines are ...

Samsung Bioepis Co., Ltd. today announced the launch of OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial), ...

On November 24, 2025, Alvotech announced that the European Commission (EC) has approved AVT03 as a biosimilar to Amgen’s PROLIA® and ...

Accord Healthcare today announced the launch of Osvyrti (denosumab), a biosimilar to Prolia® (Amgen), and Jubereq (denosumab) ...

Samsung Bioepis launches denosumab biosimilars, Obodence and Xbryk in Europe: Incheon, Korea Tuesday, December 2, 2025, 14:00 Hrs [IST] Samsung Bioepis Co., Ltd. announced the lau ...

Samsung Bioepis Co., Ltd. today announced the launch of OBODENCEtm (60 mg pre-filled syringe) and XBRYKtm (120 mg vial), denosumab biosimilars referencing Prolia and Xgeva. The products will be ...

OBODENCE (60 mg pre-filled syringe) and XBRYK (120 mg vial) become available across Europe as of December 2025 and January 2026, respectively Marks Samsung Bioepis' 10th and 11th biosimilars ...

With the festive season approaching, traditionally a risky period for people recovering from alcohol addiction, researchers ...

Evercore 8th Annual Healthcare Conference December 3, 2025 10:00 AM ESTCompany ParticipantsPeter Griffith - Executive VP & ...

Wyost is approved for the treatment of cancer-related bone disease and Jubbonti is approved to treat osteoporosis.

Sandoz Group Ltd ( ($CH:SDZ) ) has shared an update. Sandoz has launched Wyost® and Jubbonti®, two denosumab biosimilars, in Europe to treat ...